- O-3.97%
- world+12.72%
BlockBeats News, August 20th, UBS Group announced that it has raised Moderna's (MRNA.O) price target from $50 to $150.
Earlier reports stated that Moderna, in collaboration with Mercedez, has achieved significant success in a Phase III clinical trial of a personalized mRNA cancer vaccine targeting high-risk melanoma. This is the world's first mRNA cancer therapy to prove effective in a large-scale Phase III trial. Following the announcement, Moderna's stock price surged by nearly 177% in a single day.
Disclaimer: The current content is sourced from third-party perspectives or directly translated by AI from third-party perspectives. CoinEx does not guarantee the authenticity, accuracy, and originality of the content, and it does not constitute any investment advice from CoinEx. The prices of cryptocurrencies are highly volatile, please be aware of the potential risks.
- CoinsPrice24H Change